Dusk Team
iBreastExam: Globally Recognised, Locally Available
From the FDA to the World Health Organization — iBreastExam carries the most rigorous international endorsements. Here is what that means for women in Malaysia.
When choosing a health screening technology, credentials matter. iBreastExam is not a startup experiment — it is a clinically validated, award-winning device backed by over a decade of research and deployment across multiple countries.
International Recognition
iBreastExam has earned recognition from some of the world’s most respected health institutions:
- FDA (U.S. Food & Drug Administration) — cleared for breast screening use
- World Health Organization — recognised as a health equity innovation
- The World Bank — supported as part of global health access programmes
- Pennsylvania Department of Health — approved for deployment
- ACOG (American College of Obstetricians and Gynecologists) — recognised by the leading OB-GYN professional body
These are not honorary mentions. They represent rigorous review, peer-reviewed publication requirements, and clinical performance standards.
Over 1,000,000 Women Screened
To date, more than one million women worldwide have been examined using iBreastExam. The technology has been deployed in community outreach settings, under-resourced clinics, and large-scale public health programmes — precisely because it does not require heavy infrastructure.
Health Equity by Design
The mission behind iBreastExam is explicit: bring clinical-grade breast cancer screening to every woman, regardless of geography or income. That is the definition of health equity — not just making technology better, but making it accessible.
Now available in Malaysia through mobecomm.health, iBreastExam is ready to screen the communities that need it most.